GDUFA II: Priority Reviews Considered For Some ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
New pathway could restart argument between industry and FDA over what qualifies for expedited review.
You may also be interested in...
Generic Priority Review Expanded In Senate User Fee Bill
Amendment added during markup would require eight-month review of ANDAs for shortage drugs and those with limited competition, as well as pre-submission meetings.
Generic Priority Review Expanded In Senate User Fee Bill
Amendment added during markup would require eight-month review of ANDAs for shortage drugs and those with limited competition, as well as pre-submission meetings.
First Generic Approvals Decline For Fourth Straight Year At US FDA
Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.